Velmanase alfa - Chiesi Farmaceutici

Alternative Names: ALPHA-MAN project; Lamazym; Lamzede; Recombinant lysosomal alpha-D-mannosidase; Recombinant lysosomal alpha-mannosidase; rhLAMAN

Latest Information Update: 30 Jan 2018

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Zymenex A/S
Class Mannosidases; Recombinant proteins
Mechanism of Action Alpha-mannosidase replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Alpha-Mannosidosis
New Molecular Entity Yes

Highest Development Phases

Preregistration Alpha-Mannosidosis

Most Recent Events

26 Jan 2018 Committee for Medicinal Products for Human Use (CHMP) recommends approval of Velmanase alfa for Alpha-Mannosidosis (In adolescents, In adults, In children) in European Union
05 Oct 2016 Preregistration for Alpha-Mannosidosis (In adolescents, In children, In adults) in European Union (IV)
17 Aug 2016 Chiesi Farmaceutici initiates a phase II trial for Alpha-Mannosidosis (In children) in Denmark (IV) (EudraCT2016-001988-36)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.